Zogenix

Zogenix is a California-based biopharmaceutical company that develops and commercializes transformative therapies for the treatment of epilepsy and mitochondrial diseases.

Business Model:

Revenue: $81.7M

Employees: 201-500

Detailed Zogenix Information

Zogenix was acquired by UCB.
The acquisition happend on 2022-01-19.
Details of the transaction were not public

Acquirer

UCB

Geographic Data

Zogenix headquarters map

Address: 5959 Horton Street

City: Emeryville

State: CA

Zip: 94608

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$230M

Raised Total:

$494M

Metrics

3,278,779Website Global Rank

4,660Website Monthly Traffic

Twitter Followers

Description

Zogenix is a California-based biopharmaceutical company that develops and commercializes transformative therapies for the treatment of epilepsy and mitochondrial diseases.

Contact Phone:
+18582591165

Contact Email:

Zogenix went public on 11/23/2010 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
11/23/2010

Ticker Symbol:
ZGNX

IPO Price:
$4/share

Amount Raised:
$56M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
8/2018 Post-IPO Equity $312M
6/2010 Equity $15M Clarus Ventures
Domain Associates
Scale Venture Partners
Abingworth Management
Thomas McNerney & Partners
Chicago Growth Partners
7/2010 Venture Round $0 Thomas, McNerney &a; Partners
Chicago Growth Partners
Oxford Finance LLC
Scale Venture Partners
Domain Associates
Clarus Ventures
Oxford Finance LLC
Thomas, McNerney &a; Partners
Chicago Growth Partners
Oxford Finance LLC
Scale Venture Partners
Domain Associates
Clarus Ventures
Oxford Finance LLC
1/2008 Series B 4 $18M Scale Venture Partners
Domain Associates
Clarus Ventures
Abingworth
Scale Venture Partners
Domain Associates
Clarus Ventures
Abingworth
5/2009 Debt Financing $3.1M
10/2020 Debt $30M
9/2020 Debt $200M
11/2010 IPO $56M
9/2011 Post-IPO Equity $60M
12/2009 Series B $0 Chicago Growth Partners
Chicago Growth Partners
7/2010 Debt Financing 2 $35M Silicon Valley Bank
Oxford Finance LLC
Silicon Valley Bank
Oxford Finance LLC
10/2017 Post-IPO Equity $288.9M
8/2006 Series A 5 $60M Thomas, McNerney &a; Partners
Scale Venture Partners
Life Science Angels
Domain Associates
Clarus Ventures
Thomas, McNerney &a; Partners
Scale Venture Partners
Life Science Angels
Domain Associates
Clarus Ventures
7/2012 Post-IPO Equity -
10/2009 Series B 5 $36M Scale Venture Partners
Oxford Finance LLC
Domain Associates
Clarus Ventures
Abingworth
Scale Venture Partners
Oxford Finance LLC
Domain Associates
Clarus Ventures
Abingworth
9/2020 Post-IPO Equity $230M
11/2016 Post-IPO Equity $69M
7/2015 Post-IPO Equity $98.3M
3/2020 Post-IPO Equity $230.3M
7/2012 Post-IPO Equity -
7/2010 Venture Round 6 $15M Thomas, McNerney &a; Partners
Chicago Growth Partners
Oxford Finance LLC
Scale Venture Partners
Domain Associates
Clarus Ventures
Oxford Finance LLC
Thomas, McNerney &a; Partners
Chicago Growth Partners
Oxford Finance LLC
Scale Venture Partners
Domain Associates
Clarus Ventures
Oxford Finance LLC
Announced Date Name Price
8/2019 Modis Therapeutics
10/2014 Brabant pharma

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research